Deciphera Pharmaceuticals Stock Forecast, Price & News

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Deciphera Pharmaceuticals stock.
View analyst ratings for Deciphera Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Deciphera Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Deciphera Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Deciphera Pharmaceuticals saw a decline in short interest in the month of May. As of May 28th, there was short interest totaling 3,270,000 shares, a decline of 16.2% from the May 13th total of 3,900,000 shares. Based on an average trading volume of 420,100 shares, the short-interest ratio is currently 7.8 days. Approximately 8.3% of the company's stock are sold short.
View Deciphera Pharmaceuticals' Short Interest.

Deciphera Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Deciphera Pharmaceuticals.

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) released its quarterly earnings results on Tuesday, May, 4th. The company reported ($1.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.08) by $0.02. The firm earned $25.16 million during the quarter, compared to analysts' expectations of $21.35 million. Deciphera Pharmaceuticals had a negative trailing twelve-month return on equity of 45.63% and a negative net margin of 379.54%. Deciphera Pharmaceuticals's quarterly revenue was up 40474.2% compared to the same quarter last year.
View Deciphera Pharmaceuticals' earnings history.

Deciphera Pharmaceuticals' stock was trading at $44.42 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, DCPH shares have decreased by 19.5% and is now trading at $35.77.
View which stocks have been most impacted by COVID-19.

7 brokerages have issued 12-month price objectives for Deciphera Pharmaceuticals' shares. Their forecasts range from $60.00 to $78.00. On average, they expect Deciphera Pharmaceuticals' share price to reach $70.50 in the next year. This suggests a possible upside of 97.1% from the stock's current price.
View analysts' price targets for Deciphera Pharmaceuticals or view top-rated stocks among Wall Street analysts.

3 employees have rated Deciphera Pharmaceuticals CEO Steve Hoerter on Glassdoor.com. Steve Hoerter has an approval rating of 100% among Deciphera Pharmaceuticals' employees. This puts Steve Hoerter in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Deciphera Pharmaceuticals include United Therapeutics (UTHR), Ascendis Pharma A/S (ASND), Evotec (EVTCY), Sarepta Therapeutics (SRPT), Ultragenyx Pharmaceutical (RARE), Biohaven Pharmaceutical (BHVN), Perrigo (PRGO), Schrödinger (SDGR), Ionis Pharmaceuticals (IONS), TG Therapeutics (TGTX), Legend Biotech (LEGN), Reata Pharmaceuticals (RETA), I-Mab (IMAB), Galapagos (GLPG) and Blueprint Medicines (BPMC).
View all of DCPH's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Deciphera Pharmaceuticals investors own include NVIDIA (NVDA), Ionis Pharmaceuticals (IONS), Vertex Pharmaceuticals (VRTX), Allena Pharmaceuticals (ALNA), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Iovance Biotherapeutics (IOVA), SCYNEXIS (SCYX), Axsome Therapeutics (AXSM) and Exelixis (EXEL).

(DCPH) raised $101 million in an initial public offering on Thursday, September 28th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Nomura were co-managers.

Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH."

Deciphera Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Redmile Group LLC (7.51%), Franklin Resources Inc. (6.63%), BlackRock Inc. (6.01%), Alliancebernstein L.P. (3.44%), Orbimed Advisors LLC (2.38%) and Price T Rowe Associates Inc. MD (2.02%). Company insiders that own Deciphera Pharmaceuticals stock include Christopher John Morl, Daniel C Martin, Daniel Lee Flynn, James Arthur Bristol, Michael Douglas Taylor, New Leaf Venture Management Ii, Patricia L Allen and Thomas Patrick Kelly.
View institutional ownership trends for Deciphera Pharmaceuticals.

DCPH stock was sold by a variety of institutional investors in the last quarter, including UBS Asset Management Americas Inc., Redmile Group LLC, BNP Paribas Arbitrage SA, Man Group plc, Credit Suisse AG, Emerald Advisers LLC, Ameriprise Financial Inc., and Nuveen Asset Management LLC. Company insiders that have sold Deciphera Pharmaceuticals company stock in the last year include James Arthur Bristol, Michael Douglas Taylor, and Thomas Patrick Kelly.
View insider buying and selling activity for Deciphera Pharmaceuticals or view top insider-selling stocks.

DCPH stock was purchased by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Suvretta Capital Management LLC, Orbimed Advisors LLC, Franklin Resources Inc., Tekla Capital Management LLC, GW&K Investment Management LLC, Nicholas Investment Partners LP, and Eversept Partners LP.
View insider buying and selling activity for Deciphera Pharmaceuticals or or view top insider-buying stocks.

Shares of DCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DCPH stock can currently be purchased for approximately $35.77.

Deciphera Pharmaceuticals has a market capitalization of $2.07 billion and generates $42.09 million in revenue each year. The company earns $-266,490,000.00 in net income (profit) each year or ($4.78) on an earnings per share basis.

Deciphera Pharmaceuticals employs 350 workers across the globe.

The official website for Deciphera Pharmaceuticals is www.deciphera.com.

Deciphera Pharmaceuticals is headquartered at 200 SMITH STREET, Waltham MA, 02451.

Deciphera Pharmaceuticals' mailing address is 200 SMITH STREET, Waltham MA, 02451. The company can be reached via phone at (781) 209-6400 or via email at [email protected]